MARKET

CINGW

CINGW

Cingulate
NASDAQ
0.0303
-0.0024
-7.34%
Closed 12:02 03/31 EDT
OPEN
0.0370
PREV CLOSE
0.0327
HIGH
0.0370
LOW
0.0303
VOLUME
6.56K
TURNOVER
2.54K
52 WEEK HIGH
0.1750
52 WEEK LOW
0.0202
MARKET CAP
--
P/E (TTM)
-0.0068
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CINGW last week (0323-0327)?
Weekly Report · 2d ago
CINGULATE INC: FILES PROSPECTUS SUPPLEMENT RELATES TO ISSUANCE AND SALE OF COMMON STOCK OF UP TO $100 MLN FROM TIME TO TIME
Reuters · 03/24 21:20
Cingulate held special stockholder meeting to approve issuance proposal
Reuters · 03/24 21:15
Weekly Report: what happened at CINGW last week (0316-0320)?
Weekly Report · 03/23 09:18
CINGULATE INC - FILES TO OFFER AND RESALE OF UP TO 3.5 MLN SHARES BY LINCOLN PARK CAPITAL FUND - SEC FILING
Reuters · 03/20 10:03
ADHD drug developer Cingulate's Q4 net loss misses analyst expectations as G&A costs rise
Reuters · 03/18 12:10
Cingulate Q4 net loss was USD 6.27 million as G&A expenses rose 91% to USD 3.58 million
Reuters · 03/18 12:04
CINGULATE Q4 NET INCOME USD -6.3 MILLION VS. IBES ESTIMATE USD -4.52 MILLION
Reuters · 03/18 12:00
More
About CINGW
Cingulate Inc. is a biopharmaceutical company. The Company is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The Company is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.

Webull offers Cingulate Inc stock information, including NASDAQ: CINGW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CINGW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CINGW stock methods without spending real money on the virtual paper trading platform.